Pomerantz LLP is investigating claims on behalf of investors of OPKO Health, Inc. ("OPKO" or the "Company").
The investigation concerns whether OPKO and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On May 18, 2018, OPKO announced the issuance of a draft local coverage determination ("LCD") for the Company's 4Kscore test for prostate cancer. OPKO advised investors that "[t]he draft LCD is a proposed non-coverage policy for the 4Kscore test for Medicare and, prior to its effectiveness, is subject to a public comment period ending July 5, 2018." Following this announcement, OPKO's share price fell $0.89, or 18.24%, to close at $3.99 on May 18, 2018.